DFFB: A Drug Target / Disease Biomarker (G1677)

Target Name: DFFB

NCBI ID: G1677

DFFB

DFFB: A Drug Target / Disease Biomarker

DFFB, short for dopamine-facial feedback, is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Parkinson's disease. Despite its importance, little is known about DFFB and its potential as a drug target or biomarker.

One of the challenges in studying DFFB is its complex structure and the difficulty in using it as a drug target. DFFB is a transmembrane protein that is composed of four domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a cytoplasmic domain. The extracellular domain is responsible for the protein's ability to interact with other cell types, the transmembrane domain is responsible for the protein's ability to traverse the membrane, the intracellular domain is responsible for the protein's ability to enter and function within cells, and the cytoplasmic domain is responsible for the protein's ability to interact with other proteins within cells.

Despite its complex structure, DFFB is known to play a role in several important cellular processes, including the regulation of neurotransmitter release, the development and progression of neurodegenerative diseases, and the regulation of cell survival.

One of the most promising aspects of DFFB is its potential as a drug target. The use of DFFB as a drug target is based on the idea that by manipulating DFFB, it is possible to treat a variety of neurological disorders. This is because DFFB is involved in several important cellular processes that are affected in many neurological disorders, including the regulation of neurotransmitter release, the development and progression of neurodegenerative diseases, and the regulation of cell survival.

For example, DFFB has been shown to be involved in the regulation of dopamine release in the brain. Dopamine is a neurotransmitter that is involved in a variety of important cellular processes, including movement, emotion, and motivation. Imbalances in dopamine levels have been linked to a number of neurological disorders, including Parkinson's disease.

Research has shown that DFFB plays a role in regulating dopamine release in the brain by modulating the activity of a protein called TRPV1. TRPV1 is a receptor that is involved in the sensation of pain and inflammation. DFFB has been shown to interact with TRPV1 and regulate its activity. This interaction between DFFB and TRPV1 suggests that DFFB may be a useful target for drugs that are designed to treat pain and inflammation.

Another promising aspect of DFFB is its potential as a biomarker. The use of DFFB as a biomarker is based on the idea that DFFB levels can be used as a measure of the severity of a neurological disorder. This is because DFFB is expressed in the brain and is not expressed in other tissues. This makes DFFB an attractive biomarker because it is not subject to the same levels of degradation and variation as other biomarkers.

Research has shown that DFFB levels can be used as a biomarker for a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The levels of DFFB have been shown to be elevated in the brains of individuals with these disorders, which suggests that DFFB may be a useful biomarker for these disorders.

In conclusion, DFFB is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders. Despite its importance, little is known about DFFB and its potential as a drug target or biomarker. Further research is needed to fully understand the role of DFFB in these processes and to explore its potential as a drug

Protein Name: DNA Fragmentation Factor Subunit Beta

Functions: Nuclease that induces DNA fragmentation and chromatin condensation during apoptosis. Degrades naked DNA and induces apoptotic morphology

The "DFFB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DFFB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets